Glaucoma is one of the leading causes of irreversible blindness worldwide—yet it often develops silently. Many patients are unaware they have it until they experience significant vision loss. This silent progression is precisely why early diagnosis and proactive treatment are vital.
In a recent webinar, Dr. Christine Funke, a glaucoma specialist at Barnet Dulaney Perkins Eye Center, joined forces with Dr. Manjool Shah of NYU Langone Health and Dr. Inder Paul Singh of The Eye Centers of Racine and Kenosha to highlight a shift in how we approach glaucoma care. Together, they explored the benefits of early intervention using Selective Laser Trabeculoplasty (SLT)—a minimally invasive treatment proving to be a game changer for patients and physicians alike.
What Is SLT and How Does It Work?
SLT is a five-minute laser procedure that targets the eye’s natural drainage system, improving fluid outflow and reducing intraocular pressure (IOP)—the leading risk factor for glaucoma progression. Unlike traditional treatments that rely heavily on daily eye drops, SLT treats the root cause of elevated eye pressure without the challenges of long-term medication use.
Because it doesn’t damage surrounding tissue, SLT can be repeated if necessary. Most importantly, it can be performed in the early stages of glaucoma to preserve vision before it’s permanently lost.
Why Early Intervention Matters
Dr. Christine Funke is a strong advocate for early glaucoma detection and intervention. “Because glaucoma is a disease that someone may have but not know until their vision is severely affected,” she explains, “I am passionate about how to catch it and treat it early. Interventional glaucoma is imperative because the earlier we treat glaucoma, the better the long-term outcome for a patient’s vision.”
This philosophy is at the heart of the recent discussion hosted by Dr. Funke, Dr. Shah, and Dr. Singh. The webinar presented compelling evidence that SLT provides better outcomes for many patients when performed early in the disease course, compared to relying solely on eye drops as a first line of defense.
SLT vs. Eye Drops: What’s the Difference?
Eye drops have long been the go-to for glaucoma management, but they come with challenges. Patients often struggle with adherence—forgetting doses, dealing with side effects, or not using the drops correctly. Over time, this can lead to suboptimal pressure control and progressive vision loss.
SLT offers a more consistent and patient-friendly option. In just a few minutes, the laser can achieve lasting pressure reduction without the burden of daily medication. Many patients enjoy the peace of mind knowing that their eye pressure is under control without the hassle of managing multiple prescriptions.
A Better Future for Glaucoma Patients
The message from Dr. Funke and her colleagues is clear: earlier is better when treating glaucoma. SLT is helping doctors shift from a reactive approach—waiting for signs of damage—to a proactive strategy focused on preserving vision from the start.
This patient-first mindset is at the forefront of modern glaucoma care, offering:
-
A quick, in-office procedure
-
Effective pressure reduction
-
Minimal side effects
-
Repeatable treatment
-
Fewer daily medications
As Dr. Funke’s webinar illustrates, advancements like SLT are changing how we treat glaucoma and people’s lives.
Take the Next Step
If you or a loved one has been diagnosed with glaucoma or is at risk, consider asking your eye doctor about SLT. With early treatment, you may be able to protect your vision and enjoy a future free from the limitations of daily drops.
To learn more about SLT and whether it may be right for you, schedule an appointment with Dr. Christine Funke or another glaucoma specialist at Barnet Dulaney Perkins Eye Center. Your sight is too precious to wait.